Skip to main content
Premium Trial:

Request an Annual Quote

Celera's Q4 Revenues Rise Four-fold on Contribution from Acquisitions

This article has been updated from a previous version to correct Celera's full-year non-GAAP earnings per share.
 
NEW YORK (GenomeWeb News) – Celera reported after the close of the market on Wednesday that its fourth-quarter revenues quadrupled to $43.4 million from $10.2 million year over year, thanks largely to the acquisitions of Berkeley HeartLab and Atria Genetics in the second quarter of fiscal 2008.
 
Excluding the contribution of those two acquisitions, Celera’s fourth-quarter revenues were $15 million.
 
Product revenues increased 48 percent for the quarter to $9 million from $6.1 million, while revenue from royalties, licenses, and milestones doubled to $8.3 million from $4.1 million. Celera also had service revenue of $26.1 million, compared to no service revenue in the comparable period of 2007.
 
The Alameda, Calif.-based company posted a net loss of $96.8 million, or $1.21 per share, for the three-month period ended June 30, compared to a net loss of $8 million, or $.10 per share, in the prior year. The most recent quarter’s results include a $91.2 million non-cash tax charge to establish a valuation allowance against deferred tax assets as a result of the firm’s separation from Applera.
 
Celera’s R&D costs fell 30.4 percent to $9.4 million from $13.5 million in the quarter, while its SG&A expenses more than tripled to $25.1 million from $8.3 million. The firm attributed the increased SG&A spending to activities related to Berkeley HeartLab.
 
The firm will launch its KIF6 cardiac gene test later this week, Celera CEO Kathy Ordoñez said during a conference call today, and it expects the test to be a significant revenue generator from the Berkeley business.
 
For full-year 2008, Celera reported revenues of $103.2 million compared to 2007 revenues of $43.4 million. The firm’s net loss for the year was $103.2 million, or $1.30 per share, compared to a net loss of $20.6 million, or $.26 per share, for fiscal 2007. Excluding charges, earnings per share were $0.01 for the year, compared to a loss of $0.24 per share for the prior year.
 
The company’s services revenue for 2008 was $71 million, while product revenue was $32.1 million and royalty, licenses, and milestones revenue was $36.3 million.
 
Celera finished the quarter and fiscal 2008 with cash and short-term investments of approximately $335 million.

The Scan

Unique Germline Variants Found Among Black Prostate Cancer Patients

Through an exome sequencing study appearing in JCO Precision Oncology, researchers have found unique pathogenic or likely pathogenic variants within a cohort of Black prostate cancer patients.

Analysis of Endogenous Parvoviral Elements Found Within Animal Genomes

Researchers at PLOS Biology have examined the coevolution of endogenous parvoviral elements and animal genomes to gain insight into using the viruses as gene therapy vectors.

Saliva Testing Can Reveal Mosaic CNVs Important in Intellectual Disability

An Australian team has compared the yield of chromosomal microarray testing of both blood and saliva samples for syndromic intellectual disability in the European Journal of Human Genetics.

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.